NASDAQ:IART - Integra Lifesciences Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $62.95 -0.27 (-0.43 %) (As of 07/20/2018 04:00 PM ET)Previous Close$63.22Today's Range$62.89 - $63.7352-Week Range$41.51 - $67.50Volume551,000 shsAverage Volume722,366 shsMarket Capitalization$5.53 billionP/E Ratio32.55Dividend YieldN/ABeta0.63 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey. Receive IART News and Ratings via Email Sign-up to receive the latest news and ratings for IART and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryHealth Care Equipment SectorMedical SymbolNASDAQ:IART CUSIP45798520 Webwww.integralife.com Phone609-275-0500 Debt Debt-to-Equity Ratio1.77 Current Ratio2.53 Quick Ratio1.66 Price-To-Earnings Trailing P/E Ratio32.55 Forward P/E Ratio26.12 P/E Growth1.89 Sales & Book Value Annual Sales$1.19 billion Price / Sales4.66 Cash Flow$3.1225 per share Price / Cash20.16 Book Value$12.26 per share Price / Book5.13 Profitability EPS (Most Recent Fiscal Year)$1.94 Net Income$64.74 million Net Margins5.39% Return on Equity17.90% Return on Assets6.14% Miscellaneous Employees4,400 Outstanding Shares87,880,000Market Cap$5,531.04 Integra Lifesciences (NASDAQ:IART) Frequently Asked Questions What is Integra Lifesciences' stock symbol? Integra Lifesciences trades on the NASDAQ under the ticker symbol "IART." When did Integra Lifesciences' stock split? How did Integra Lifesciences' stock split work? Integra Lifesciences's stock split before market open on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were distributed to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of Integra Lifesciences stock prior to the split would have 200 shares after the split. How were Integra Lifesciences' earnings last quarter? Integra Lifesciences Holdings Corp (NASDAQ:IART) posted its quarterly earnings data on Wednesday, April, 25th. The life sciences company reported $0.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.49 by $0.09. The life sciences company earned $357.10 million during the quarter, compared to the consensus estimate of $349.15 million. Integra Lifesciences had a net margin of 5.39% and a return on equity of 17.90%. The firm's revenue was up 38.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.39 EPS. View Integra Lifesciences' Earnings History. When is Integra Lifesciences' next earnings date? Integra Lifesciences is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Integra Lifesciences. What guidance has Integra Lifesciences issued on next quarter's earnings? Integra Lifesciences updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided EPS guidance of $2.34-2.42 for the period, compared to the Thomson Reuters consensus estimate of $2.33. The company issued revenue guidance of $1.47-1.49 billion, compared to the consensus revenue estimate of $1.48 billion. What price target have analysts set for IART? 14 analysts have issued 1 year target prices for Integra Lifesciences' shares. Their forecasts range from $50.00 to $74.00. On average, they anticipate Integra Lifesciences' share price to reach $59.6667 in the next year. This suggests that the stock has a possible downside of 5.2%. View Analyst Ratings for Integra Lifesciences. What is the consensus analysts' recommendation for Integra Lifesciences? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Integra Lifesciences in the last year. There are currently 11 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." What are Wall Street analysts saying about Integra Lifesciences stock? Here are some recent quotes from research analysts about Integra Lifesciences stock: 1. According to Zacks Investment Research, "Significant gross margin contractions caused by escalating costs have been a major headwind for Integra Lifesciences. Added to this, a tough competitive landscape adds to the company’s woes. Despite these hurdles, Integra Lifesciences has outperformed its industry over the last three months. Solid growth across all business segments has been the key growth catalyst. Integra’s successful progress with its channel expansion strategy and Codman integration buoy optimism. Notably, the company announced plans within Orthopedics and Tissue Technologies segment to expand its sales channel, improve focus and competitiveness and better align the company’s product portfolio with clinical customers. Moreover, the strong investments in research and development is encouraging. The company’s promising guidance also instills confidence in the stock." (7/10/2018) 2. Cantor Fitzgerald analysts commented, "We maintain our Neutral rating and 12-month price target of $59 on IART. Although we view IART’s long-range plan as impressive, we believe execution over the next few quarters is critical to restoring investor confidence in the stock. We think it is appropriate to stay on the sidelines at this time, but we might become more positive on the stock if the company were to execute on its integration and salesforce restructuring goals. We think IART is fairly valued at current levels, appropriately balancing the long-term opportunities with the risk of near-term disruption from the Codman acquisition and the changes to the OTT sales channel structure." (6/12/2018) Who are some of Integra Lifesciences' key competitors? Some companies that are related to Integra Lifesciences include Agilent Technologies (A), Waters (WAT), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), Bio-Rad Laboratories, Inc. Class B (BIO.B), PerkinElmer (PKI), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO) and Eyepoint Pharmaceuticals (EYPT). Who are Integra Lifesciences' key executives? Integra Lifesciences' management team includes the folowing people: Mr. Peter J. Arduini, Pres, CEO & Director (Age 53)Dr. Richard E. Caruso Ph.D., Founder and Chairman Emeritus (Age 75)Mr. Glenn G. Coleman, Corp. VP & CFO (Age 50)Mr. Richard D. Gorelick, Corp. VP of Admin., Gen. Counsel & Sec. (Age 57)Mr. Daniel L. Reuvers, Corp. VP and Pres of Specialty Surgical Solutions (Age 55) Has Integra Lifesciences been receiving favorable news coverage? Media stories about IART stock have trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Integra Lifesciences earned a media sentiment score of 0.02 on Accern's scale. They also gave news stories about the life sciences company an impact score of 45.38 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days. Who are Integra Lifesciences' major shareholders? Integra Lifesciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (1.08%), Retirement Systems of Alabama (0.10%), Mitsubishi UFJ Asset Management UK Ltd. (0.02%), Louisiana State Employees Retirement System (0.02%), Amalgamated Bank (0.02%) and Municipal Employees Retirement System of Michigan (0.02%). Company insiders that own Integra Lifesciences stock include Barbara B Hill, Christian S Schade, Daniel L Reuvers, Donald E Morel Jr, Glenn Coleman, James M Sullivan, Jeffrey Mosebrook, Joseph Vinhais, Keith Bradley, Peter J Arduini, Raymond G Murphy, Richard D Gorelick, Richard E Caruso and Stuart Essig. View Institutional Ownership Trends for Integra Lifesciences. Which institutional investors are selling Integra Lifesciences stock? IART stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Fisher Asset Management LLC, Louisiana State Employees Retirement System and Municipal Employees Retirement System of Michigan. Company insiders that have sold Integra Lifesciences company stock in the last year include Christian S Schade, Daniel L Reuvers, Glenn Coleman, Jeffrey Mosebrook, Joseph Vinhais, Keith Bradley, Richard D Gorelick, Richard E Caruso and Stuart Essig. View Insider Buying and Selling for Integra Lifesciences. Which institutional investors are buying Integra Lifesciences stock? IART stock was acquired by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Mitsubishi UFJ Asset Management UK Ltd., Amalgamated Bank, Bank of Montreal Can, World Asset Management Inc and LS Investment Advisors LLC. Company insiders that have bought Integra Lifesciences stock in the last two years include Barbara B Hill and Donald E Morel Jr. View Insider Buying and Selling for Integra Lifesciences. How do I buy shares of Integra Lifesciences? Shares of IART can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Integra Lifesciences' stock price today? One share of IART stock can currently be purchased for approximately $62.95. How big of a company is Integra Lifesciences? Integra Lifesciences has a market capitalization of $5.53 billion and generates $1.19 billion in revenue each year. The life sciences company earns $64.74 million in net income (profit) each year or $1.94 on an earnings per share basis. Integra Lifesciences employs 4,400 workers across the globe. How can I contact Integra Lifesciences? Integra Lifesciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The life sciences company can be reached via phone at 609-275-0500 or via email at [email protected] MarketBeat Community Rating for Integra Lifesciences (NASDAQ IART)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 323 (Vote Outperform)Underperform Votes: 344 (Vote Underperform)Total Votes: 667MarketBeat's community ratings are surveys of what our community members think about Integra Lifesciences and other stocks. Vote "Outperform" if you believe IART will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IART will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: Are analyst ratings accurate?